Centocor ( CNTO ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO )

CNTO 0.00001000

0.0%

Feb 6 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Pancho Villa who wrote (532)	2/1/1998 2:37:00 PM
From: PawPr	Read Replies (2) of 965

I think any merger between Glaxo and Smithkline would come under serious antitrust scrutiny. For example, Glaxo ( with Zovirax and Valtrex ) and Smithkline ( with Famvir ) have the only effective systemic antiherpes drugs on the market. I bet the feds would make them sell off some overlapping product lines before a merger could go through. As for IPIC, it seems to me that all the bad news is out, they've got a stroke drug before the FDA that they claim works, and the chart looks like its bottoming. I'd cover any short position; it looks too risky from here out. As for me, I've got two positions in companies that are being bought out ( DEC and IPCI ), so I'll have some extra $$$ to invest soon. Any ideas? BT

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next